Fc and Glycoengineered Antibodies Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Engineering, Type of Therapy, Therapeutic Area, Route of Administration and Key Geographical Regions

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control

2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation
2.7. Key Market Segmentations

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.2.3. Foreign Exchange Impact
3.2.2.4. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.2.5. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Recession
3.2.3.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.3.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.4. Inflation
3.2.4.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.4.2. Potential Impact of Inflation on the Market Evolution

4.1. Chapter Overview

5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. Historical Timeline of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Fc Region and Effector Functions
5.6.1. Types of Fc Receptors
5.6.2. Engineering of the Fc Region
5.6.2.1. Glycoengineering
5.6.2.2. Protein Engineering
5.6.2.3. Isotype Chimerism
5.7. Future Perspective

6.1. Chapter Overview
6.2. Fc Engineered and Glycoengineered Antibodies: Overall Pipeline
6.2.1. Analysis by Stage of Development
6.2.2. Analysis by Type of Antibody
6.2.3. Analysis by Type of Engineering
6.2.4. Analysis by Impact of Engineering
6.2.5. Analysis by Biological Target
6.2.6. Analysis by Type of Therapy
6.2.7. Analysis by Target Disease Indication
6.2.8. Analysis by Therapeutic Area
6.2.9. Analysis by Route of Administration
6.2.10. Popular Fc Engineering Technologies: Analysis by Number of Marketed Drugs and Development Programs
6.3. Fc Engineered and Glycoengineered Antibodies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Leading Developers: Analysis by Number of Drugs

7.1. Chapter Overview
7.2. Detailed Company Profiles of Leading Fc Engineered and Glycoengineered Antibody Drug Developers
7.2.1. AbbVie
7.2.1.1. Company Overview
7.2.1.2. Financial Information
7.2.1.3. Drug Portfolio
7.2.1.3.1. Drug Profile: Skyrizi
7.2.1.4. Recent Developments and Future Outlook
7.2.2. Alexion Pharmaceuticals
7.2.2.1. Company Overview
7.2.2.2. Drug Portfolio
7.2.2.2.1. Drug Profile: Soliris
7.2.2.2.2. Drug Profile: Ultomiris
7.2.2.3. Recent Developments and Future Outlook
7.2.3. AstraZeneca
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Drug Portfolio
7.2.3.3.1. Drug Profile: Beyfortus
7.2.3.3.2. Drug Profile: Imfinzi
7.2.3.3.3. Drug Profile: Fasenra
7.2.3.3.4. Drug Profile: Saphnelo
7.2.3.4. Recent Developments and Future Outlook
7.2.4. Genentech
7.2.4.1. Company Overview
7.2.4.2. Financial Information
7.2.4.3. Drug Portfolio
7.2.4.3.1. Drug Profile: Gazyva
7.2.4.3.2. Drug Profile: Ocrevus
7.2.4.3.3. Drug Profile: Tecentriq
7.2.4.4. Recent Developments and Future Outlook
7.2.5. MacroGenics
7.2.5.1. Company Overview
7.2.5.2. Financial Information
7.2.5.3. Drug Portfolio
7.2.5.3.1. Drug Profile: Margenza
7.2.5.3.2. Drug Profile: MGA-271
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Kyowa Kirin
7.2.6.1. Company Overview
7.2.6.2. Financial Information
7.2.6.3. Drug Portfolio
7.2.6.3.1. Drug Profile: POTELIGEO
7.2.6.4. Recent Developments and Future Outlook
7.3. Short Company Profiles of Leading Fc Engineered and Glycoengineered Antibody Drug Developers
7.3.1. Akeso Biopharma
7.3.1.1. Company Overview
7.3.1.2. Drug Portfolio
7.3.1.2.1. Drug Profile: Penpulimab
7.3.2. Amgen
7.3.2.1. Company Overview
7.3.2.2. Drug Portfolio
7.3.2.2.1. Drug Profile: Bemarituzuman
7.3.2.2.2. Drug Profile: STEAP1 XmAb Antibody
7.3.2.2.3. Drug Profile: FPA157
7.3.3. Boehringer Ingelheim
7.3.3.1. Company Overview
7.3.3.2. Drug Portfolio
7.3.3.2.2. Drug Profile: Spesolimab
7.3.4. MorphoSys
7.3.4.1. Company Overview
7.3.4.2. Drug Portfolio
7.3.4.2.1. Drug Portfolio: Tafasitamab
7.3.5. Xemcor
7.3.5.1. Company Overview
7.3.5.2. Drug Portfolio
7.3.5.2.1. Drug Portfolio: Tidutamab
7.3.5.2.2. Drug Portfolio: XmAb22841
7.3.5.2.3. Drug Portfolio: XmAb23104
7.3.5.2.4. Drug Portfolio: Plamotamab
7.3.5.2.5. Drug Portfolio: Vibecotamab
7.3.5.2.6. Drug Portfolio: RO7310729
7.3.5.2.7. Drug Portfolio: XmAb20717
7.3.5.2.8. Drug Portfolio: XmAb819
7.3.5.2.9. Drug Portfolio: XmAb27564
7.3.5.2.10. Drug Portfolio: VRC01LS

8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Fc Engineered and Glycoengineered Antibodies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
8.3.3. Analysis by Trial Phase
8.3.4. Analysis of Number of Patients Enrolled by Trial Phase
8.3.5. Analysis by Trial Registration Year and Trial Phase
8.3.6. Analysis by Trial Status
8.3.7. Analysis by Patient Gender
8.3.8. Analysis by Target Indication
8.3.9. Analysis by Study Design
8.3.9.1. Analysis by Type of Trial Masking
8.3.9.2. Analysis by Type of Intervention Model
8.3.9.3. Analysis by Type of Trial Purpose
8.3.9.4. Analysis by Design Allocation
8.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
8.3.10.1. Analysis by Leading Industry Players
8.3.10.2. Analysis by Leading Non-Industry Players
8.3.11. Analysis by Geography
8.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
8.3.11.2. Analysis of Patients Enrolled by Trial Status and Geography

9.1. Chapter Overview
9.2. Partnership Models
9.3. Fc Engineered and Glycoengineered Antibodies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Engineering
9.3.5. Analysis by Therapeutic Area
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.7.1. Intracontinental and Intercontinental Agreements
9.3.7.2. Local and International Agreements

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Fc Engineered and Glycoengineered Antibodies: Grant Analysis
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Funding Institute Center
10.3.4. Analysis by Support Period
10.3.5. Analysis by Funding Institute Center and Support Period
10.3.6. Analysis by Type of Grant Application
10.3.7. Analysis by Purpose of Grant Award
10.3.8. Analysis by Activity Code
10.3.9. Analysis by Study Section Involved
10.3.10. Most Popular NIH Departments: Analysis by Number of Grants
10.3.10.1. Prominent Program Officers: Analysis By Number of Grants
10.3.10.2. Popular Recipient Organizations: Analysis by Number of Grants
10.3.10.3. Popular Recipient Organizations: Analysis by Grant Amount
10.3.11. Popular Recipient Organizations: Distribution by States in the US

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Fc Engineered and Glycoengineered Antibodies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis by Patent Application Year
11.3.3. Analysis by Granted Patents and Patent Applications, 2019-2023
11.3.4. Analysis by Patent Jurisdiction
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Type of Applicant
11.3.7. Leading Industry Players: Analysis by Number of Patents
11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
11.3.9. Leading Patent Assignees: Analysis by Number of Patents
11.3.10. Patent Benchmarking Analysis
11.3.10.1. Analysis by Patent Characteristics
11.3.11. Patent Valuation
11.3.12. Leading Patents by Number of Citations

12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035)
12.3.1. Scenario Analysis
12.3.1.1. Conservative Scenario
12.3.1.2. Optimistic Scenario
12.4. Key Market Segmentations

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering, 2024 and 2035
13.3.1. Fc Engineered Antibodies Market, 2024-2035
13.3.2. Glycoengineered Antibodies Market, 2024-2035
13.4. Data Triangulation and Validation

14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035
14.3.1. Fc Engineered and Glycoengineered Market for Monotherapy, 2024-2035
14.3.2. Fc Engineered and Glycoengineered Market for Combination Therapy, 2024-2035
14.3.3. Fc Engineered and Glycoengineered Market for Both, 2024-2035
14.4. Data Triangulation and Validation

15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035
15.3.1. Fc Engineered and Glycoengineered Market for Oncological Disorders, 2024-2035
15.3.2. Fc Engineered and Glycoengineered Market for Dermatological Disorders, 2024-2035
15.3.3. Fc Engineered and Glycoengineered Market for Autoimmune Disorders, 2024-2035
15.3.4. Fc Engineered and Glycoengineered Market for Rare Disorders, 2024-2035
15.3.5. Fc Engineered and Glycoengineered Market for Other Disorders, 2024-2035
15.4. Data Triangulation and Validation

16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035
16.3.1. Fc Engineered and Glycoengineered Market for Intravenous Route, 2024-2035
16.3.2. Fc Engineered and Glycoengineered Market for Subcutaneous Route, 2024-2035
16.3.3. Fc Engineered and Glycoengineered Market for Intramuscular Route, 2024-2035
16.4. Data Triangulation and Validation

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035
17.3.1. Fc Engineered and Glycoengineered Market in North America, 2024-2035
17.3.2. Fc Engineered and Glycoengineered Market in Europe, 2024-2035
17.3.3. Fc Engineered and Glycoengineered Market in Asia-Pacific, 2024-2035
17.3.4. Fc Engineered and Glycoengineered Market in Rest of the World, 2024-2035
17.4. Data Triangulation and Validation

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Sales Forecast
18.3.1. AK-105 Sales Forecast
18.3.2. BeyfortusTM Sales Forecast
18.3.3. Briumvi® Sales Forecast
18.3.4. Fasenra® Sales Forecast
18.3.5. Gazyva® Sales Forecast
18.3.6. Imfinzi® Sales Forecast
18.3.7. Margenza Sales Forecast
18.3.8. Monjuvi® Sales Forecast
18.3.9. Ocrevus® Sales Forecast
18.3.10. POTELIGEO® Sales Forecast
18.3.11. Saphnelo® Sales Forecast
18.3.12. Skyrizi® Sales Forecast
18.3.13. Soliris® Sales Forecast
18.3.14. Tecentriq® Sales Forecast
18.3.15. Tislelizumab Sales Forecast
18.3.16. Tzield® Sales Forecast
18.3.17. Ultomiris® Sales Forecast
18.3.18. Uplizna® Sales Forecast
18.4. Phase III Fc Engineered and Glycoengineered Antibodies Market: Sales Forecast
18.4.1. Clazakizumab Sales Forecast
18.4.2. FPA144 Sales Forecast
18.4.3. Skyrizi Sales Forecast
18.4.4. TQ-B2450 Sales Forecast
18.4.5. Visterra Sales Forecast
18.5. Data Triangulation and Validation

19.1. Chapter Overview

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1. Lessons Learnt from Past Recessions
Figure 4.1. Executive Summary: Overall Market Landscape
Figure 4.2. Executive Summary: Clinical Trial Analysis
Figure 4.3. Executive Summary: Partnerships and Collaborations
Figure 4.4. Executive Summary: Grant Analysis
Figure 4.5. Executive Summary: Patent Analysis
Figure 4.6. Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1. Structure of an Antibody
Figure 5.2. Historical Timeline of Antibody Development
Figure 5.3. Main Functions of Antibodies
Figure 6.1. Fc Engineered and Glycoengineered Antibodies: Distribution by Stage of Development
Figure 6.2. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Antibody
Figure 6.3. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Engineering
Figure 6.4. Fc Engineered and Glycoengineered Antibodies: Distribution by Impact of Engineering
Figure 6.5. Fc Engineered and Glycoengineered Antibodies: Distribution by Biological Target
Figure 6.6. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Therapy
Figure 6.7. Fc Engineered and Glycoengineered Antibodies: Distribution by Target Disease Indication
Figure 6.8. Fc Engineered and Glycoengineered Antibodies: Distribution by Therapeutic Area
Figure 6.9. Fc Engineered and Glycoengineered Antibodies: Distribution by Route of Administration
Figure 6.10. Popular Fc Engineered Technologies: Distribution by Number of Marketed Drugs Development Programs
Figure 6.11. Fc Engineered and Glycoengineered Antibodies: Distribution by Year of Establishment
Figure 6.12. Fc Engineered and Glycoengineered Antibodies: Distribution by Company Size
Figure 6.13. Fc Engineered and Glycoengineered Antibodies: Distribution by Location of Headquarters
Figure 6.14. World Map Representation: Analysis by Geography
Figure 6.15. Leading Developers: Distribution by Number of Drugs
Figure 7.1. AbbVie: Annual Revenues, FY 2019-FY 2023 (USD Billion)
Figure 7.2. AstraZeneca: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Figure 7.3. Roche (Parent Company of Genentech): Annual Revenues, FY 2019 - FY 2023 (CHF Billion)
Figure 7.4. MacroGenics: Annual Revenues, FY 2019 - 9M FY 2023 (USD Million)
Figure 7.5. Kyowa Kirin: Annual Revenues, FY 2019 - FY 2023 (YEN Billion)
Figure 8.1. Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2015-2024
Figure 8.2. Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Pre-2015-2024
Figure 8.3. Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4. Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 8.5. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2015-2024
Figure 8.6. Clinical Trial Analysis: Distribution by Trial Status
Figure 8.7. Clinical Trial Analysis: Distribution by Patient Gender
Figure 8.8. Clinical Trial Analysis: Distribution by Target Indication
Figure 8.9. Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 8.10. Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 8.11. Clinical Trial Analysis: Distribution by Trial Purpose
Figure 8.12. Clinical Trial Analysis: Distribution by Design Allocation
Figure 8.13. Leading Industry Players: Distribution by Number of Registered Trials
Figure 8.14. Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.15. Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 8.16. Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2024
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4. Partnerships and Collaborations: Distribution by Type of Engineering
Figure 9.5. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.6. Most Active Players: Distribution by Number of Partnerships
Figure 9.7. Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 9.8. Partnerships and Collaborations: Local and International Agreements
Figure 10.1. Grant Analysis: Cumulative Year-wise Trend, 2019-2024
Figure 10.2. Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Figure 10.3. Grants Analysis: Distribution by Funding Institute Center
Figure 10.4. Grants Analysis: Distribution by Support Period
Figure 10.5. Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 10.6. Grants Analysis: Distribution by Type of Grant Application
Figure 10.7. Grants Analysis: Distribution by Purpose of Grant Award
Figure 10.8. Grants Analysis: Distribution by Activity Code
Figure 10.9. Grants Analysis: Distribution by Study Section Involved
Figure 10.10. Most Popular Departments: Distribution by Number of Grants
Figure 10.11. Prominent Program Officers: Distribution by Number of Grants
Figure 10.12. Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.13. Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 10.14. Popular Recipient Organizations: Distribution by States in the US
Figure 11.1. Patent Analysis: Distribution by Type of Patent
Figure 11.2. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2024
Figure 11.3. Patent Analysis: Distribution by Patent Application Year, Pre-2019-2023
Figure 11.4. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
Figure 11.5. Patent Analysis: Distribution by Patent Jurisdiction
Figure 11.6. Patent Analysis: Distribution by CPC Symbols
Figure 11.7. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 11.8. Leading Industry Players: Distribution by Number of Patents
Figure 11.9. Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10. Leading Individual Assignees: Distribution by Number of Patents
Figure 11.11. Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 11.12. Patent Benchmarking Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 11.13. Patent Analysis: Distribution by Patent Age
Figure 11.14. Fc Engineered and Glycoengineered Antibodies: Patent Valuation
Figure 12.1. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 12.2. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Conservative Scenario (USD Billion)
Figure 12.3. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Optimistic Scenario (USD Billion)
Figure 13.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering,2024 and 2035
Figure 13.2. Fc Engineered and Glycoengineered Antibodies Market for Fc Engineered Antibodies, 2024-2035 (USD Billion)
Figure 13.3. Fc Engineered and Glycoengineered Antibodies Market for Glycoengineered Antibodies, 2024-2035 (USD Billion)
Figure 14.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035
Figure 14.2. Fc Engineered and Glycoengineered Antibodies Market for Monotherapy, 2024-2035 (USD Billion)
Figure 14.3. Fc Engineered and Glycoengineered Antibodies Market for Combination Therapy, 2024-2035 (USD Billion)
Figure 14.4. Fc Engineered and Glycoengineered Antibodies Market for Both, 2024-2035 (USD Billion)
Figure 15.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035
Figure 15.2. Fc Engineered and Glycoengineered Antibodies Market for Oncological Disorders, 2024-2035 (USD Billion)
Figure 15.3. Fc Engineered and Glycoengineered Antibodies Market for Dermatological Disorders, 2024-2035 (USD Billion)
Figure 15.4. Fc Engineered and Glycoengineered Antibodies Market for Autoimmune Disorders, 2024-2035 (USD Billion)
Figure 15.5. Fc Engineered and Glycoengineered Antibodies Market for Rare Disorders, 2024-2035 (USD Billion)
Figure 15.6. Fc Engineered and Glycoengineered Antibodies Market for Other Disorders, 2024-2035 (USD Billion)
Figure 16.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035
Figure 16.2. Fc Engineered and Glycoengineered Antibodies Market for Intravenous Route, 2024-2035 (USD Billion)
Figure 16.3. Fc Engineered and Glycoengineered Antibodies Market for Subcutaneous Route, 2024-2035 (USD Billion)
Figure 16.4. Fc Engineered and Glycoengineered Antibodies Market for Intramuscular Route, 2024-2035 (USD Billion)
Figure 17.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035
Figure 17.2. Fc Engineered and Glycoengineered Antibodies Market in North America, 2024-2035 (USD Billion)
Figure 17.3. Fc Engineered and Glycoengineered Antibodies Market in Europe, 2024-2035 (USD Billion)
Figure 17.4. Fc Engineered and Glycoengineered Antibodies Market in Asia-Pacific, 2024-2035 (USD Billion)
Figure 17.5. Fc Engineered and Glycoengineered Antibodies Market in Rest of the World, 2024-2035 (USD Billion)
Figure 18.1. Commercialized Fc Engineered and Glycoengineered Antibodies Market: AK-105 Sales Forecast, 2021-2035 (USD Billion)
Figure 18.2. Commercialized Fc Engineered and Glycoengineered Antibodies Market: BeyfortusTM Sales Forecast, 2022-2035 (USD Billion)
Figure 18.3. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Briumvi® Sales Forecast, 2023-2035 (USD Billion)
Figure 18.4. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Fasenra® Sales Forecast, 2018-2035 (USD Billion)
Figure 18.5. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Gazyva® Sales Forecast, 2017-2035 (USD Billion)
Figure 18.6. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Imfinzi® Sales Forecast, 2018-2035 (USD Billion)
Figure 18.7. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Margenza Sales Forecast, 2021-2035 (USD Billion)
Figure 18.8. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Monjuvi® Sales Forecast, 2020-2035 (USD Billion)
Figure 18.9. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ocrevus® Sales Forecast, 2017-2035 (USD Billion)
Figure 18.10. Commercialized Fc Engineered and Glycoengineered Antibodies Market: POTELIGEO® Sales Forecast, 2019-2035 (USD Billion)
Figure 18.11. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Saphnelo® Sales Forecast, 2021-2035 (USD Billion)
Figure 18.12. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Skyrizi® Sales Forecast, 2020-2035 (USD Billion)
Figure 18.13. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Soliris® Sales Forecast, 2017-2035 (USD Billion)
Figure 18.14. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tecentriq® Sales Forecast, 2017-2035 (USD Billion)
Figure 18.15. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tislelizumab Sales Forecast, 2020-2035 (USD Billion)
Figure 18.16. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tzield® Sales Forecast, 2023-2035 (USD Billion)
Figure 18.17. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ultomiris® Sales Forecast, 2019-2035 (USD Billion)
Figure 18.18. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Uplizna® Sales Forecast, 2020-2035 (USD Billion)
Figure 18.19. Phase III Fc Engineered and Glycoengineered Antibodies Market: Clazakizumab Sales Forecast, 2030-2035 (USD Billion)
Figure 18.20. Phase III Fc Engineered and Glycoengineered Antibodies Market: FPA144 Sales Forecast, 2027-2035 (USD Billion)
Figure 18.21. Phase III Fc Engineered and Glycoengineered Antibodies Market: Skyrizi Sales Forecast, 2024-2035 (USD Billion)
Figure 18.22. Phase III Fc Engineered and Glycoengineered Antibodies Market: TQ-B2450 Sales Forecast, 2027-2035 (USD Billion)
Figure 18.23. Phase III Fc Engineered and Glycoengineered Antibodies Market: VIS649 Sales Forecast, 2028-2035 (USD Billion)
Figure 19.1. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Overall Market Landscape
Figure 19.2. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Clinical Trial Analysis
Figure 19.3. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Partnerships and Collaborations
Figure 19.4. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Grant Analysis
Figure 19.5. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Patent Analysis
Figure 19.6. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Market Sizing and Opportunity Analysis (I/II)
Figure 19.7. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Market Sizing and Opportunity Analysis (II/II)

Table 1.1. Fc and Glycoengineered Antibodies Market: Report Attribute / Market Segment
Table 5.1. Features of Different Isotypes of Antibodies
Table 5.2. Features of Engineered Fc Regions
Table 6.1. Fc Engineered and Glycoengineered Antibodies: Overall Pipeline
Table 6.2. Fc Engineered and Glycoengineered Antibodies: Information on Type of Engineering, Impact of Engineering and Fc Engineering Technology
Table 6.3. Fc Engineered and Glycoengineered Antibodies: List of Developers
Table 7.1. Fc Engineered and Glycoengineered Antibodies: List of Drug Developers Profiled
Table 7.2. AbbVie: Company Snapshot
Table 7.3. Drug Profile: Skyrizi
Table 7.4. AbbVie: Recent Developments and Future Outlook
Table 7.5. Alexion Pharmaceuticals: Company Snapshot
Table 7.6. Drug Profile: Soliris
Table 7.7. Drug Profile: Ultomiris
Table 7.8. AstraZeneca: Company Snapshot
Table 7.9. Drug Profile: Beyfortus
Table 7.10. Drug Profile: Imfinzi
Table 7.11. Drug Profile: Fasenra
Table 7.12. Drug Profile: Saphnelo
Table 7.13. AstraZeneca: Recent Developments and Future Outlook
Table 7.14. Genentech: Company Snapshot
Table 7.15. Drug Profile: Gazyva
Table 7.16. Drug Profile: Ocrevus
Table 7.17. Drug Profile: Tecentriq
Table 7.18. Genentech: Recent Developments and Future Outlook
Table 7.19. MacroGenics: Company Snapshot
Table 7.20. Drug Profile: Margenza
Table 7.21. Drug Profile: MGA-271
Table 7.22. MacroGenics: Recent Developments and Future Outlook
Table 7.23. Kyowa Kirin: Company Snapshot
Table 7.24. Drug Profile: POTELIGEO
Table 7.25. Kyowa Kirin: Recent Developments and Future Outlook
Table 7.26. Akeso Biopharma: Company Snapshot
Table 7.27. Drug Profile: Penpulimab
Table 7.28. Amgen: Company Snapshot
Table 7.29. Drug Profile: Bmarituzumab
Table 7.30. Drug Profile: XmAb Antibody
Table 7.31. Drug Profile: FPA157
Table 7.32. Boehringer Ingelheim: Company Snapshot
Table 7.33. Drug Profile: Spesolimab
Table 7.34. MorphoSys: Company Snapshot
Table 7.35. Drug Profile: Tafasitamab
Table 7.36. Xencor: Company Snapshot
Table 7.37. Drug Profile: Tidutamab
Table 7.38. Drug Profile: XmAb22841
Table 7.39. Drug Profile: XmAb23104
Table 7.40. Drug Profile: Plamotamab
Table 7.41. Drug Profile: Vibecotamab
Table 7.42. Drug Profile: RO7310729
Table 7.43. Drug Profile: XmAb20717
Table 7.44. Drug Profile: XmAb819
Table 7.45. Drug Profile: XmAb27564
Table 7.46. Drug Profile: VRC01LS
Table 9.1. Fc Engineered and Glycoengineered Antibodies: List of Partnerships and Collaborations, 2016-2024
Table 9.2. Partnerships and Collaborations: Information on Type of Engineering and Therapeutic Area
Table 11.1. Patent Analysis: Top CPC Sections
Table 11.2. Patent Analysis: Top CPC Symbols
Table 11.3. Patent Analysis: Top CPC Codes
Table 11.4. Patent Analysis: Summary of Benchmarking Analysis
Table 11.5. Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6. Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.7. Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 21.1. Fc Engineered and Glycoengineered Antibodies: Distribution by Stage of Development
Table 21.2. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Antibody
Table 21.3. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Engineering
Table 21.4. Fc Engineered and Glycoengineered Antibodies: Distribution by Impact of Engineering
Table 21.5. Fc Engineered and Glycoengineered Antibodies: Distribution by Biological Target
Table 21.6. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Therapy
Table 21.7. Fc Engineered and Glycoengineered Antibodies: Distribution by Target Disease Indication
Table 21.8. Fc Engineered and Glycoengineered Antibodies: Distribution by Therapeutic Area
Table 21.9. Fc Engineered and Glycoengineered Antibodies: Distribution by Route of Administration
Table 21.10. Popular Fc Engineering Technologies: Distribution by Number of Development Programs
Table 21.11. Fc Engineered and Glycoengineered Antibodies: Distribution by Year of Establishment
Table 21.12. Fc Engineered and Glycoengineered Antibodies: Distribution by Company Size
Table 21.13. Fc Engineered and Glycoengineered Antibodies: Distribution by Location of Headquarters
Table 21.14. AbbVie: Annual Revenues, FY 2019-FY 2023 (USD Billion)
Table 21.15. AstraZeneca: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Table 21.16. Roche (Parent Company of Genentech): Annual Revenues, FY 2019 - FY 2023 (CHF Billion)
Table 21.17. MacroGenics: Annual Revenues, FY 2019 - 9M FY 2023 (USD Million)
Table 21.18. Kyowa Kirin: Annual Revenues, FY 2019 - FY 2023 (YEN Billion)
Table 21.19. Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2015-2024
Table 21.20. Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Pre-2015-2024
Table 21.21. Clinical Trial Analysis: Distribution by Trial Phase
Table 21.22. Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Table 21.23. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2015-2024
Table 21.24. Clinical Trial Analysis: Distribution by Trial Status
Table 21.25. Clinical Trial Analysis: Distribution by Patient Gender
Table 21.26. Clinical Trial Analysis: Distribution by Target Indication
Table 21.27. Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 21.28. Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 21.29. Clinical Trial Analysis: Distribution by Trial Purpose
Table 21.30. Clinical Trial Analysis: Distribution by Design Allocation
Table 21.31. Leading Industry Players: Distribution by Number of Registered Trials
Table 21.32. Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 21.33. Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 21.34. Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 21.35. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2024
Table 21.36. Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.37. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 21.38. Partnerships and Collaborations: Distribution by Type of Engineering
Table 21.39. Partnerships and Collaborations: Distribution by Therapeutic Area
Table 21.40. Most Active Players: Distribution by Number of Partnerships
Table 21.41. Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 21.42. Partnerships and Collaborations: Local and International Agreements
Table 21.43. Grant Analysis: Cumulative Year-wise Trend, 2019-2024
Table 21.44. Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Table 21.45. Grants Analysis: Distribution by Funding Institute Center
Table 21.46. Grants Analysis: Distribution by Support Period
Table 21.47. Grants Analysis: Distribution by Funding Institute Center and Support Period
Table 21.48. Grants Analysis: Distribution by Type of Grant Application
Table 21.49. Grants Analysis: Distribution by Purpose of Grant Award
Table 21.50. Grants Analysis: Distribution by Activity Code
Table 21.51. Grants Analysis: Distribution by Study Section Involved
Table 21.52. Most Popular Departments: Distribution by Number of Grants
Table 21.53. Prominent Program Officers: Distribution by Number of Grants
Table 21.54. Popular Recipient Organizations: Distribution by Number of Grants
Table 21.55. Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Table 21.56. Popular Recipient Organizations: Distribution by States in the US
Table 21.57. Patent Analysis: Distribution by Type of Patent
Table 21.58. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2024
Table 21.59. Patent Analysis: Distribution by Patent Application Year, Pre-2019-2023
Table 21.60. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
Table 21.61. Patent Analysis: Distribution by Patent Jurisdiction
Table 21.62. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 21.63. Leading Industry Players: Distribution by Number of Patents
Table 21.64. Leading Non-Industry Players: Distribution by Number of Patents
Table 21.65. Leading Individual Assignees: Distribution by Number of Patents
Table 21.66. Patent Analysis: Distribution by Patent Age
Table 21.67. Fc Engineered and Glycoengineered Antibodies: Patent Valuation
Table 21.68. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035) (USD Billion)
Table 21.69. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Conservative Scenario (USD Billion)
Table 21.70. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Optimistic Scenario (USD Billion)
Table 21.71. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering, 2024 and 2035 (USD Billion)
Table 21.72. Fc Engineered and Glycoengineered Antibodies Market for Fc Engineered Antibodies, 2024-2035 (USD Billion)
Table 21.73. Fc Engineered and Glycoengineered Antibodies Market for Glycoengineered Antibodies, 2024-2035 (USD Billion)
Table 21.74. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035 (USD Billion)
Table 21.75. Fc Engineered and Glycoengineered Antibodies Market for Monotherapy, 2024-2035 (USD Billion)
Table 21.76. Fc Engineered and Glycoengineered Antibodies Market for Combination Therapy, 2024-2035 (USD Billion)
Table 21.77. Fc Engineered and Glycoengineered Antibodies Market for Both, 2024-2035 (USD Billion)
Table 21.78. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035 (USD Billion)
Table 21.79. Fc Engineered and Glycoengineered Antibodies Market for Oncological Disorders, 2024-2035 (USD Billion)
Table 21.80. Fc Engineered and Glycoengineered Antibodies Market for Dermatological Disorders, 2024-2035 (USD Billion)
Table 21.81. Fc Engineered and Glycoengineered Antibodies Market for Autoimmune Disorders, 2024-2035 (USD Billion)
Table 21.82. Fc Engineered and Glycoengineered Antibodies Market for Rare Disorders, 2024-2035 (USD Billion)
Table 21.83. Fc Engineered and Glycoengineered Antibodies Market for Other Disorders, 2024-2035 (USD Billion)
Table 21.84. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035 (USD Billion)
Table 21.85. Fc Engineered and Glycoengineered Antibodies Market for Intravenous Route, 2024-2035 (USD Billion)
Table 21.86. Fc Engineered and Glycoengineered Antibodies Market for Subcutaneous Route, 2024-2035 (USD Billion)
Table 21.87. Fc Engineered and Glycoengineered Antibodies Market for Intramuscular Route, 2024-2035 (USD Billion)
Table 21.88. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035 (USD Billion)
Table 21.89. Fc Engineered and Glycoengineered Antibodies Market in North America, 2024-2035 (USD Billion)
Table 21.90. Fc Engineered and Glycoengineered Antibodies Market in Europe, 2024-2035 (USD Billion)
Table 21.91. Fc Engineered and Glycoengineered Antibodies Market in Asia-Pacific, 2024-2035 (USD Billion)
Table 21.92. Fc Engineered and Glycoengineered Antibodies Market in Rest of the World, 2024-2035 (USD Billion)
Table 21.93. Commercialized Fc Engineered and Glycoengineered Antibodies Market: AK-105 Sales Forecast, 2021-2035 (USD Billion)
Table 21.94. Commercialized Fc Engineered and Glycoengineered Antibodies Market: BeyfortusTM Sales Forecast, 2022-2035 (USD Billion)
Table 21.95. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Briumvi® Sales Forecast, 2023-2035 (USD Billion)
Table 21.96. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Fasenra® Sales Forecast, 2018-2035 (USD Billion)
Table 21.97. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Gazyva® Sales Forecast, 2017-2035 (USD Billion)
Table 21.98. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Imfinzi® Sales Forecast, 2018-2035 (USD Billion)
Table 21.99. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Margenza Sales Forecast, 2021-2035 (USD Billion)
Table 21.100. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Monjuvi® Sales Forecast, 2020-2035 (USD Billion)
Table 21.101. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ocrevus® Sales Forecast, 2017-2035 (USD Billion)
Table 21.102. Commercialized Fc Engineered and Glycoengineered Antibodies Market: POTELIGEO® Sales Forecast, 2019-2035 (USD Billion)
Table 21.103. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Saphnelo® Sales Forecast, 2021-2035 (USD Billion)
Table 21.104. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Skyrizi® Sales Forecast, 2020-2035 (USD Billion)
Table 21.105. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Soliris® Sales Forecast, 2017-2035 (USD Billion)
Table 21.106. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tecentriq® Sales Forecast, 2017-2035 (USD Billion)
Table 21.107. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tislelizumab Sales Forecast, 2020-2035 (USD Billion)
Table 21.108. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tzield® Sales Forecast, 2023-2035 (USD Billion)
Table 21.109. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ultomiris® Sales Forecast, 2019-2035 (USD Billion)
Table 21.110. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Uplizna® Sales Forecast, 2020-2035 (USD Billion)
Table 21.111. Phase III Fc Engineered and Glycoengineered Antibodies Market: Clazakizumab Sales Forecast, 2030-2035 (USD Billion)
Table 21.112. Phase III Fc Engineered and Glycoengineered Antibodies Market: FPA144 Sales Forecast, 2027-2035 (USD Billion)
Table 21.113. Phase III Fc Engineered and Glycoengineered Antibodies Market: Skyrizi Sales Forecast, 2024-2035 (USD Billion)
Table 21.114. Phase III Fc Engineered and Glycoengineered Antibodies Market: TQ-B2450 Sales Forecast, 2027-2035 (USD Billion)
Table 21.115. Phase III Fc Engineered and Glycoengineered Antibodies Market: VIS649 Sales Forecast, 2028-2035 (USD Billion)